Comparative Docking Studies on Erlotinib (Synthetic drug) and Curcumin (Natural drug) Against the Lung Cancer (TCF21)

Authors

  • Dr. D. Sarasa  Assistant Professor, PG and Research department of Zoology, Quaid-e-millath government college for women, Chennai, Tamil Nadu, India

Keywords:

TCF21, Curcumin, Erlotinib, Autodock.

Abstract

Lung cancer is the second leading cause of death worldwide. In cancer, cells divide and grow uncontrollably, forming malignant tumors, and invade nearby parts of the body. The cancer may also spread to more distant parts of the body through the lymphatic system or bloodstream. A number of undesired side effects sometimes occur during chemotherapy. There has been a vast growth in the field of herbal medicine and these drugs popularly are increasing both in developing and developed countries because of their natural origin, more therapeutic effect and less side effects. Since ancient cultures, tribal people methodically collected information on herbs and developed well-defined herbal drugs for the treatment of many diseases. Mostly, cancer patients are gaining benefit from treatment with herbal medicine. In the present study the anti cancer activity of the existing drug (Erlotinib) and natural compound Curcumin (Curcuma longa) were compared based on the protein ligand interactions were carried out using bioinformatics software and tools. Protein ligand interactions in the present investigation revealed that curcumin is more effective to bind the gene TCF21 comparatively erlotinib.

References

  1. Gupta, S.K., Singh, A. and Srivastava, M. (2009). Designing of drug for removal of methylation from Tcf21 gene in lung cancer. Online Journal of Bioinformatics. Vol.11 (1): 149-155
  2. Jerah, A., Hobani, Y., Kumar, B.V. and Bidwai, A. (2015). Curcumin binds in silico to anti-cancer drug target enzyme MMP-3 (human stromelysin-1) with affinity comparable to two known inhibitors of the enzyme. Bioinformation. 11(8):387-392.
  3. Fong, D., Yeh, A., Naftalovich, R., Choi, T.H. and Chan, M.M. (2010). Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: Towards targeting of cancer stem cells with phytochemicals. Cancer Lett. 293:65–72.
  4. Kakarala, M., Brenner, D.E., Korkaya, H., Cheng, C., Tazi, K., Ginestier, C., Liu, S., Dontu, G. and Wicha, M.S. (2010). Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 122:777–785.
  5. Lin, Y.G. et al. (2007). Clin. Cancer Res., 13: 3423 [PMID 17545551].
  6. Kravchenko, J., Akushevich, I. and Manton, K.G. (2009). Cancer mortality and morbidity patterns in the U. S. population: an interdisciplinary approach. Berlin: Springer.
  7. Anand, P., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Tharakan, S.T., Lai, O.S., Sung, B. and Aggarwal, B.B. (2008). Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res., 25(9): 2097–2116.
  8. Subramanian, J. and Govindan, R. (2007). Lung cancer in never smokers: a review. J Clin Oncol. Feb, 10; 25(5):561-70.
  9. Lu, C1, Lee, J.J., Komaki, R., Herbst, R.S., Feng, L., Evans, W.K., Choy, H., Desjardins, P., Esparaz, B.T., Truong, M.T., Saxman, S., Kelaghan, J., Bleyer, A. and Fisch, M.J. (2010). Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.  J. Natl. Cancer Inst. Jun, 16; 102(12):859-65. doi: 10.1093/jnci/djq179. Epub 2010 May 26.
  10. Brown DW, Anda RF, Felitti VJ, Edwards VJ, Malarcher AM, Croft JB, Giles WH.Adverse childhood experiences are associated with the risk of lung cancer: a prospective cohort study. BMC Public Health. 2010 Jan 19;10:20. doi: 10.1186/1471-2458-10-20.
  11. Davis, R.J.O. and Lee ycg (2010). Oxford textbook medicine (5th ed). OUP oxford. ISBN 978.
  12. Jemal, A., Sandler, A.B., Putnam, J.B. and Johnson, D.H. (2007). The rationale for adjuvaent chemotheraphy in stage I non small cell lung cancer. Journal of thoracic Oncology, 2 (5):377-383.
  13. Lim, W.Y. and Seow, A. (2012). Biomass fuels and lung cancer. Respirology., Jan;17(1):20-31. doi: 10.1111/j.1440-1843.2011.02088.
  14. Collins, L.G., Haines, C., Perkel, R. and Enck, R.E. (2007). Lung cancer: diagnosis and management. American family physician, 75 (1):56-63.
  15. Dudley Joel, 2013. Exploring personel Genomics. Oxford University Press pp. 25 ISBN 978-0-19-964448-3.
  16. Ferlay, J., Shin, H.R. and Bray, F. (2010). Estimates of worldwide burden of cancer in 2008. International journal of cancer, 127 (12): 2893-2917
  17. Greene and Fredrick, L. (2002). AJCC cancer staging manual. Berlin:  Springer –verlag. ISBN-0-387-95271-3.
  18. Mehra, R. and Treat, J. (2008). Fishmans Pulmonary Diseases and Disorders (4th ed.) MCGraw –Hill. pp.1876.
  19. Narayan, S and Curcumin (2004)a multi functional chemopreventive agent, blocks growth of colon cancer cells by targeting B- catenin-mediated transactivation and cell-cell adhesion pathways Journal of molecular histology., 35:301-307.
  20. Rami –Porta, R., Crowley, J.J. and Goldstraw, P. (2009). The revised TNM staging system for lung cancer. Annals of thoracic and Cardiovascular Surgery. 15 (1): 4-9.
  21. Yahya Hobani Ahmed Jerah Anil Bidwai. (2017). A comparative molecular docking study of methotrexate  to dihydrofolate reductase. Bioinformation. 13 (3): 63-66.

International Journal of Scientific Research in Science, Engineering and Technology

Downloads

Published

2017-08-31

Issue

Volume 3, Issue 5, July-August-2017

Section

Research Articles

License

Copyright (c) IJSRSET

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Dr. D. Sarasa, " Comparative Docking Studies on Erlotinib (Synthetic drug) and Curcumin (Natural drug) Against the Lung Cancer (TCF21), International Journal of Scientific Research in Science, Engineering and Technology(IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 3, Issue 5, pp.521-527, July-August-2017.